MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41409-026-02980-4

Медицинская библиотека · Bone marrow transplantation · 2026

Incidence, clinical risk factors, and biomarkers of SOS/VOD following allogeneic HSCT in adults. A real-life study by the Spanish group of HSCT and cell therapy (GETH-TC).

Pérez-Martínez Ariadna, Cabrero Mónica, Montoro Juan, Sánchez-Escamilla Miriam, Cuesta María Ángeles, de Soria Valle Gómez-García, González-Sierra Pedro, Humala Karem, López-Godino Oriana, Luna de Abia Alejandro, López-Corral Lucía, Sanz Jaime, Pascual María Jesús, Piñana José Luis, Bermúdez Arancha, Bellón José María, Filaferro Silvia, Orti Guillermo, Balsalobre Pascual, Solano Carlos

СтатьяПеревод пока не подготовлен

Аннотация

Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) may occur after allo-HSCT. This retrospective study of 793 allo-HSCT performed in adult patients analyzes the impact of clinical risk factors and the EASIX score on the incidence and outcomes of SOS/VOD using Real-World data (GETH-TC registry). Severity and clinical risk factors were defined according to the EBMT-2023 criteria. The EASIX score was calculated at three time points after allo-HSCT (EASIX-day 0, d + 7, d + 14). SOS/VOD developed in 79 patients (10%), at a median time of 15 days. The cumulative incidence of SOS/VOD at 30 and 90 days post-HSCT was 8.58% and 9.97%, respectively. Defibrotide was used in 44 patients (56%) who developed SOS/VOD. Patients with SOS/VOD experienced an increased risk of NRM (HR 5.56; p < 0.001). Multivariate analysis confirmed the prognostic value for SOS/VOD incidence of second or subsequent HSCT, use of parenteral nutrition, high tacrolimus/sirolimus levels, INR > 1.5 before SOS, as well as day 0 EASIX ≥ 2 (sHR 1.67; p = 0.036), d + 7 EASIX ≥ 6 (sHR 2.86; p < 0.001), and d + 14 EASIX ≥ 6 (sHR 2.87; p = 0.003). In conclusion, SOS/VOD incidence is similar to previous series and significantly impacts NRM. EASIX score was validated as a risk factor of SOS/VOD.

Для цитирования: Pérez-Martínez Ariadna, Cabrero Mónica, Montoro Juan, Sánchez-Escamilla Miriam, Cuesta María Ángeles, de Soria Valle Gómez-García, González-Sierra Pedro, Humala Karem, López-Godino Oriana, Luna de Abia Alejandro, López-Corral Lucía, Sanz Jaime, Pascual María Jesús, Piñana José Luis, Bermúdez Arancha, Bellón José María, Filaferro Silvia, Orti Guillermo, Balsalobre Pascual, Solano Carlos. Incidence, clinical risk factors, and biomarkers of SOS/VOD following allogeneic HSCT in adults. A real-life study by the Spanish group of HSCT and cell therapy (GETH-TC).. Bone marrow transplantation. 2026. DOI: 10.1038/s41409-026-02980-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.